These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 38683493

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
    Fiander MDJ, Bhan V, Stewart SA, Parks NE.
    Can J Neurol Sci; 2019 Jul; 46(4):455-458. PubMed ID: 31113500
    [Abstract] [Full Text] [Related]

  • 24. Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
    Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, Wiendl H.
    BMC Neurol; 2015 Jun 23; 15():96. PubMed ID: 26099927
    [Abstract] [Full Text] [Related]

  • 25. MYL-1402O: A Bevacizumab Biosimilar.
    Lee A.
    Target Oncol; 2022 Jan 23; 17(1):85-88. PubMed ID: 34910269
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. SB2: An Infliximab Biosimilar.
    Lamb YN, Scott LJ, Deeks ED.
    BioDrugs; 2017 Oct 23; 31(5):461-464. PubMed ID: 28803431
    [Abstract] [Full Text] [Related]

  • 29. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S, Comar M, Ferrante P.
    Immunotherapy; 2017 Jan 23; 9(2):157-171. PubMed ID: 28004598
    [Abstract] [Full Text] [Related]

  • 30. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA.
    Mult Scler Relat Disord; 2018 May 23; 22():27-34. PubMed ID: 29524759
    [Abstract] [Full Text] [Related]

  • 31. SB3 (Ontruzant®): A Trastuzumab Biosimilar.
    Lamb YN.
    BioDrugs; 2018 Jun 23; 32(3):293-296. PubMed ID: 29796993
    [Abstract] [Full Text] [Related]

  • 32. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
    John N, Carroll A, Brownlee WJ, Chataway J.
    J Neurol Neurosurg Psychiatry; 2019 Dec 23; 90(12):1376-1378. PubMed ID: 31079064
    [No Abstract] [Full Text] [Related]

  • 33. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Trojano M, Ramió-Torrentà L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC, Ren Z, Muralidharan KK, Licata S, Gafson AR.
    Mult Scler; 2021 Dec 23; 27(14):2240-2253. PubMed ID: 33821693
    [Abstract] [Full Text] [Related]

  • 34. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P, Lasek-Bal A.
    Med Sci Monit; 2016 Nov 10; 22():4277-4282. PubMed ID: 27829656
    [Abstract] [Full Text] [Related]

  • 35. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E, Papadimitropoulou K, Jarrett J, Bending M, Firth Z, Allen F, Adlard N.
    BMJ Open; 2017 Mar 10; 7(3):e013430. PubMed ID: 28283486
    [Abstract] [Full Text] [Related]

  • 36. FKB327: An Adalimumab Biosimilar.
    Al-Salama ZT.
    BioDrugs; 2019 Feb 10; 33(1):113-116. PubMed ID: 30712241
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.
    Fakih AU, Sahraian MA, Paybast S, Naser Moghadasi A.
    Mult Scler Relat Disord; 2023 Mar 10; 71():104564. PubMed ID: 36863084
    [Abstract] [Full Text] [Related]

  • 40. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA, Aldosari F, Althobaiti AH, Abdullah FM, Aljarallah S, Alkhawajah NM, Alanazi M, AlRuthia Y.
    BMC Health Serv Res; 2023 May 26; 23(1):552. PubMed ID: 37237257
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.